This study aims to evaluate clinical outcomes of colistin versus colistin in combination with cefoperazone-sulbactam for patients with MDR-AB VAP treatment.
MDR-AB (multidrug-resistant Acinetobacter baumannii) has been an increasingly common cause of ventilator-associated pneumonia (VAP) in intensive care unit (ICU). Colistin remains the last available antibiotic choice. Unfortunately, colistin monotherapy is often inadequate for microbiologic eradication and a risk factor of nephrotoxicity and for heteroresistance.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
80
Combination therapy
Monotherapy
Shaheed Mohtarma Benazir Bhutto Institue of Trauma
Karachi, Pakistan
Clinical response
Clinical response was defined as observable improvement in the patient's clinical signs/symptoms, including absence of fever (temp\<38ºC) for three consecutive days or more, and decreasing amount and purulence of tracheal secretions
Time frame: within one week
Radiological response
Radiological response was defined as improvement/resolution of pulmonary infiltrates, as noted on chest x-rays following treatment.
Time frame: within one week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.